a C57BL/6J mice (n = 5) were immunized against ovalbumin with either KISIMA-OVA given s.c. (K) or VSV-GP-OVA (V) administered i.m. on days 0, 7, and 14 (dotted lines) or left untreated (mock). The fraction of OVA-specific cells among CD8+ T cells in peripheral blood is shown. Two-way ANOVA with Tukey’s multiple comparisons (*, p < 0.05; **, p < 0.01). b–g C57BL/6J mice were immunized with KISIMA-OVA (s.c.) on day 0 and 14 and VSV-GP-OVA was administered either i.m. or i.v. on day 7 as indicated by dotted lines (n = 5 per treatment group, n = 2 for mock). b The frequency of OVA-specific CD8+ T cells in circulation is depicted. Two-way ANOVA with Sidak’s multiple comparison (**, p < 0.01). c, d The number of OVA-specific CD8+ T cells in the (c) spleen and (d) bone marrow of immunized mice was measured 19 weeks post prime. One-way ANOVA with Tukey’s multiple comparison (**, p < 0.01). e–g The number of OVA-specific CD8+ T cells with effector (KLRG1+CD127−) and memory precursor (CD127+) phenotype in (e) peripheral blood (cells/ml), (f) spleen and (g) bone marrow 19 weeks after prime is shown. Two-way ANOVA with Sidak’s multiple comparison (****, p < 0.0001). (h, i) C57BL/6J mice were vaccinated against (h) Adpgk and Reps1 neoantigens or (i) HPV-E7 with either (h) KISIMA-Mad24 or (i) KISIMA-HPV given s.c. (K) or (h) VSV-GP-Mad24 or (i) VSV-GP-HPV administered i.v. (V) on day 0 and as indicated with dotted lines. The frequency of circulating CD8+ T cells specific for (h) Adpgk (n = 5 per group) and (i) HPV-E7 (n = 7 per group) is depicted. Two-way ANOVA (h) and one-way ANOVA (i) with Tukey’s multiple comparison was performed (*** p < 0.001; ****p < 0.0001) and significance compared to mock is shown. All data shown as mean ± SEM. Studies (a, c–g) were performed once, studies (b, i) were independently repeated once, study (h) was repeated once with the listed groups except VKK, which was only included once. Source data and p-values are provided in the Source Data File.